WASHINGTON DC (May 12, 2020) — During COVID-19, the US Food and Drug Administration will continue to utilize and implement additional alternative inspection-tools and approaches while postponing domestic and foreign routine-surveillance inspections. This will continue as local, national, and international conditions warrant, with the exception of certain mission-critical inspections.







